The approval of tocilizumab was made with breakthrough therapy and priority review designations.
PORTLAND - The effects of a topical JAK inhibitor on facial vitiligo in four patients were promising.
PORTLAND, ORE. – A study of patients with pyoderma gangrenosum provides information about comorbidities to look out for in this population.
News from the FDA/CDC
The risk of lower limb amputation associated with canagliflozin is now great enough to receive a boxed warning.
The investigational agent CC-220 showed some efficacy but also important safety caveats in a 12-week, phase II trial.
SYDNEY, AUSTRALIA – Satisfaction with the effects of botulinum toxin therapy for axillary hyperhidrosis was high in a retrospective study of...